• Je něco špatně v tomto záznamu ?

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

D. Schadendorf, R. Dummer, KT. Flaherty, C. Robert, A. Arance, JWB. de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, N. Yamazaki, P. Queirolo, C. Guenzel, A. Polli, M. Thakur, A. di Pietro, PA. Ascierto

. 2024 ; 204 (-) : 114073. [pub] 20240424

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013639

BACKGROUND: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma. We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff). METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450 mg once daily (QD) plus binimetinib 45 mg twice daily (BID) (n = 192), vemurafenib 960 mg BID (n = 191), or encorafenib monotherapy 300 mg QD (n = 194). No prior BRAF/MEK inhibitor was allowed. RESULTS: Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively. Median melanoma-specific survival (95 % CI) was 36.8 months (27.7-51.5 months) in the encorafenib plus binimetinib arm and 19.3 months (14.8-25.9 months) in the vemurafenib arm. Thirty-four long-term responders (complete/partial response ongoing at 7 years) were identified across arms. CONCLUSIONS: This is the longest follow-up from a phase III trial of BRAF/MEK inhibitor combination in BRAF V600E/K-mutant metastatic melanoma. Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib. Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders. Interactive data visualization is available at the COLUMBUS dashboard (https://clinical-trials.dimensions.ai/columbus7/).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013639
003      
CZ-PrNML
005      
20240905134007.0
007      
ta
008      
240725e20240424enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2024.114073 $2 doi
035    __
$a (PubMed)38723373
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schadendorf, Dirk $u University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany; National Center for Tumor Diseases West, Campus Essen, and Research Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen, Germany. Electronic address: dirk.schadendorf@uk-essen.de
245    10
$a COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma / $c D. Schadendorf, R. Dummer, KT. Flaherty, C. Robert, A. Arance, JWB. de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, N. Yamazaki, P. Queirolo, C. Guenzel, A. Polli, M. Thakur, A. di Pietro, PA. Ascierto
520    9_
$a BACKGROUND: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma. We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff). METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450 mg once daily (QD) plus binimetinib 45 mg twice daily (BID) (n = 192), vemurafenib 960 mg BID (n = 191), or encorafenib monotherapy 300 mg QD (n = 194). No prior BRAF/MEK inhibitor was allowed. RESULTS: Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively. Median melanoma-specific survival (95 % CI) was 36.8 months (27.7-51.5 months) in the encorafenib plus binimetinib arm and 19.3 months (14.8-25.9 months) in the vemurafenib arm. Thirty-four long-term responders (complete/partial response ongoing at 7 years) were identified across arms. CONCLUSIONS: This is the longest follow-up from a phase III trial of BRAF/MEK inhibitor combination in BRAF V600E/K-mutant metastatic melanoma. Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib. Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders. Interactive data visualization is available at the COLUMBUS dashboard (https://clinical-trials.dimensions.ai/columbus7/).
650    _2
$a lidé $7 D006801
650    12
$a melanom $x farmakoterapie $x genetika $x mortalita $7 D008545
650    12
$a karbamáty $x aplikace a dávkování $x škodlivé účinky $7 D002219
650    12
$a protoonkogenní proteiny B-Raf $x genetika $7 D048493
650    12
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    12
$a benzimidazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D001562
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a vemurafenib $x aplikace a dávkování $x škodlivé účinky $7 D000077484
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a nádory kůže $x farmakoterapie $x genetika $x patologie $x mortalita $7 D012878
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dummer, Reinhard $u University Hospital Zurich, Zurich, Switzerland
700    1_
$a Flaherty, Keith T $u Massachusetts General Hospital Cancer Center, Boston, MA, USA
700    1_
$a Robert, Caroline $u Gustave Roussy and Paris-Saclay University, Villejuif, France
700    1_
$a Arance, Ana $u Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
700    1_
$a de Groot, Jan Willem B $u Isala Oncology Center, Zwolle, the Netherlands
700    1_
$a Garbe, Claus $u University Hospital Tübingen, Tübingen, Germany
700    1_
$a Gogas, Helen J $u National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Gutzmer, Ralf $u Hannover Medical School, Hannover, and Ruhr-University Bochum, Minden Campus, Germany
700    1_
$a Krajsová, Ivana $u University Hospital Prague, Prague, Czech Republic
700    1_
$a Liszkay, Gabriella $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Loquai, Carmen $u University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Mandalà, Mario $u University of Perugia, Perugia, Italy
700    1_
$a Yamazaki, Naoya $u National Cancer Center Hospital, Tokyo, Japan
700    1_
$a Queirolo, Paola $u Melanoma and Sarcoma Division, IEO European Institute of Oncology, IRCCS, Milan, Italy
700    1_
$a Guenzel, Carolin $u Pfizer, New York, NY, USA
700    1_
$a Polli, Anna $u Pfizer, Milan, Italy
700    1_
$a Thakur, Mahgull $u Pfizer, Sandwich, UK
700    1_
$a di Pietro, Alessandra $u Pfizer, Milan, Italy
700    1_
$a Ascierto, Paolo A $u Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
773    0_
$w MED00009626 $t European journal of cancer $x 1879-0852 $g Roč. 204 (20240424), s. 114073
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38723373 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134001 $b ABA008
999    __
$a ok $b bmc $g 2143436 $s 1225505
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 204 $c - $d 114073 $e 20240424 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace